Clinical Trials Logo

Hemangioendothelioma clinical trials

View clinical trials related to Hemangioendothelioma.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05228015 Active, not recruiting - Solid Tumor Clinical Trials

Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects With Advanced Solid Tumors

Start date: January 7, 2022
Phase: Phase 1
Study type: Interventional

This is a Phase 1, first-in-human (FIH) clinical study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and preliminary antitumor activity of IK-930, an oral TEAD inhibitor, administered orally (PO) as monotherapy in subjects with advanced solid tumors with or without gene alterations in the Hippo pathway for whom there are no further treatment options known to confer clinical benefit. The study consists of two phases, an initial Dose Escalation phase followed by a Dose Expansion phase.

NCT ID: NCT03331250 Active, not recruiting - Angiosarcoma Clinical Trials

Eribulin in Angiosarcoma and Epithelioid Hemangioendothelioma (EHE)

Start date: January 18, 2018
Phase: Phase 2
Study type: Interventional

This research study is studying a drug as a possible treatment for Angiosarcoma or Epithelioid hemangioendothelioma (EHE). -The drug involved in this study is Eribulin

NCT ID: NCT00975819 Active, not recruiting - Clinical trials for Microcystic Lymphatic Malformation

Safety and Efficacy Study of Sirolimus in Complicated Vascular Anomalies

Start date: October 2009
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine if the use of sirolimus in the treatment of children and young adults with complicated vascular anomalies will prove to be safe and provide objective response resulting in improved clinical status and quality of life. Funding Source - FDA OOPD (Food and Drug Administration - Office of Orphan Products Development)